Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited)

v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Purchase of Arbuz shares
Purchase of ReKassa shares
Total equity attributable to the shareholders'
Total equity attributable to the shareholders'
Purchase of Arbuz shares
Total equity attributable to the shareholders'
Purchase of ReKassa shares
Common Stock
Additional paid in capital
Retained earnings
Retained earnings
Purchase of Arbuz shares
Retained earnings
Purchase of ReKassa shares
Accumulated other comprehensive loss
Non- controlling interest
Non- controlling interest
Purchase of Arbuz shares
Non- controlling interest
Purchase of ReKassa shares
Beginning balance (in shares) at Mar. 31, 2022             59,542,212,000                
Equity, beginning of period at Mar. 31, 2022 $ 546,608     $ 553,603     $ 59 $ 174,745 $ 441,924     $ (63,125) $ (6,995)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation 10,746     10,746       10,746              
Contribution of shareholder 677     677       677              
Acquisition of insurance companies (26,588)     (26,588)       (26,588)              
Foreign currency translation adjustments, net of tax effect (301)     (301)               (301)      
Other comprehensive income 2,506     2,506               2,506      
Net income/(loss) 148,683     150,191         150,191       (1,508)    
Ending balance (in shares) at Dec. 31, 2022             59,542,212,000                
Equity, end of period at Dec. 31, 2022 682,331     690,834     $ 59 159,580 592,115     (60,920) (8,503)    
Beginning balance (in shares) at Sep. 30, 2022             59,542,212,000                
Equity, beginning of period at Sep. 30, 2022 621,331     629,370     $ 59 155,635 529,251     (55,575) (8,039)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation 3,945     3,945       3,945              
Foreign currency translation adjustments, net of tax effect (5,611)     (5,611)               (5,611)      
Other comprehensive income 266     266               266      
Net income/(loss) 62,400     62,864         62,864       (464)    
Ending balance (in shares) at Dec. 31, 2022             59,542,212,000                
Equity, end of period at Dec. 31, 2022 $ 682,331     690,834     $ 59 159,580 592,115     (60,920) (8,503)    
Beginning balance (in shares) at Mar. 31, 2023 59,659,191           59,659,191,000                
Equity, beginning of period at Mar. 31, 2023 $ 770,736     777,285     $ 59 164,162 647,064     (34,000) (6,549)    
Equity, beginning of period (Cumulative adjustment from adoption of ASC 326) at Mar. 31, 2023 (22,772)     (22,772)         (22,772)            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation 3,303     3,303       3,303              
Disposal of FF Ukraine 0     (6,549)         (6,549)       6,549    
Purchase of subsidiary shares   $ 9,097 $ 256   $ 5,457 $ 0       $ 5,457     $ 3,640 $ 256
Foreign currency translation adjustments, net of tax effect (3,593)     (3,593)               (3,593)      
Other comprehensive income 2,748     2,748               2,748      
Net income/(loss) $ 279,475     280,317         280,317       (842)    
Ending balance (in shares) at Dec. 31, 2023 59,659,191           59,659,191,000                
Equity, end of period at Dec. 31, 2023 $ 1,039,250     1,036,196     $ 59 167,465 903,517     (34,845) 3,054    
Beginning balance (in shares) at Sep. 30, 2023             59,659,191,000                
Equity, beginning of period at Sep. 30, 2023 914,431     911,084     $ 59 166,426 807,149     (62,550) 3,347    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation 1,039     1,039       1,039              
Foreign currency translation adjustments, net of tax effect 28,100     28,100               28,100      
Other comprehensive income (395)     (395)               (395)      
Net income/(loss) $ 96,075     96,368         96,368       (293)    
Ending balance (in shares) at Dec. 31, 2023 59,659,191           59,659,191,000                
Equity, end of period at Dec. 31, 2023 $ 1,039,250     $ 1,036,196     $ 59 $ 167,465 $ 903,517     $ (34,845) $ 3,054